🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,387 results for “Le” Clear

  1. Start antiplatelet monotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Intracerebral Hemorrhage

    phase 3 small molecule completed

    1 trial

  2. Sterile 0.9% (w/v) sodium chloride solution in single-use PFS, Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation

    GlaxoSmithKline

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  3. Sterile normal saline (0.9% sodium chloride solution), ADX-324

    Lacuna Pharma Pty Ltd

    Hereditary Angioedema

    phase 3 small molecule active

    1 trial

  4. Subcutaneous Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  5. Sufentanil 30 MCG Sublingual Tablet

    United Therapeutics Europe Ltd

    Traumatic Injury

    phase 3 small molecule completed

    1 trial

  6. Sufentanil Mylan 50 microgrammes/ml solution injectable, MORPHINE HYDROCHLORIDE, CHLORURE DE SODIUM 0,9 % LAVOISIER, solution pour perfusion

    Pari Pharma GmbH

    vaso-occlusive crisis due to sickle cell disease

    phase 3 small molecule active

    1 trial

  7. Sugammadex 100 mg/ml solution for injection, Rocuronium bromide 10 mg/ml solution for injection/infusion

    Istituto Gentili S.r.l.

    patients scheduled to undergo elective surgical procedures with general anesthesia

    phase 3 small molecule active

    1 trial

  8. Sunitinib AqVida 12,5 mg Hartkapseln, QINLOCK 50 mg tablets

    Lacuna Pharma Pty Ltd

    Patients with Advanced Gastrointestinal Stromal Tumors

    phase 3 small molecule active

    1 trial

  9. Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  10. Suprefact Depot 9,45 mg implantat, Pamorelin 11,25 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 22,5 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Pamorelin 3,75 mg, poeder en oplosmiddel voor suspensie voor injectie, met verlengde afgifte., Eligard 45 mg poeder en oplosmiddel voor oplossing voor injectie, LEUPRORELIN ACETATE, CAMCEVI 42 mg prolonged-release suspension for injection, Gonapeptyl Depot 3,75 mg poeder en oplosmiddel

    Disc Medicine

    low-volume metastatic castration-sensitive prostate cancer

    phase 3 small molecule active

    1 trial

  11. Surovatamig

    AstraZeneca

    Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV

    phase 3 small molecule active

    1 trial

  12. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    diabetic foot syndrome, lower limb ischemia

    phase 3 small molecule active

    1 trial

  13. Sutent 12.5 mg hard capsules, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PAZOPANIB , Sutent 25 mg hard capsules

    Incyte

    Locally advanced/metastatic renal cell carcinoma

    phase 3 small molecule active

    1 trial

  14. Sutent 50 mg hard capsules, Alectinib (Alecensa), Sutent 12.5 mg hard capsules, Cotellic, Sutent 25 mg hard capsules, RO7047650, Cotellic, Alecensa 150 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, Zelboraf, Sutent 12.5 mg hard capsules, Venclexta, Venclyxto, Alecensa 150 mg hard capsules, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, RO7250726, Sutent 25 mg hard capsules, ALIMTA 500 mg powder for concentrate for solution for infusion, Sutent 50 mg hard capsules, Ze

    Hoffmann-La Roche

    Advanced Malignancies

    phase 3 small molecule active

    1 trial

  15. Suxiao Jiuxin Pill

    The First People's Hospital of Lianyungang

    Acute Mountain Sickness

    phase 3 small molecule active

    1 trial

  16. Symbicort Turbuhaler

    AstraZeneca

    Asthma

    phase 3 small molecule completed

    1 trial

  17. Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension, BFF (PT009), BD ( PT008), SALBUTAMOL, Placebo MDI and empty TBH devices (only for training purposes)

    AstraZeneca AB

    Inadequately Controlled Asthma

    phase 3 small molecule active

    1 trial

  18. T89 Placebo; capsules contain brown coated dripping pills., Nitroglycerin Orifarm 0,5 mg tabletes lietošanai zem mēles

    Lacuna Pharma Pty Ltd

    Stable Angina Pectoris

    phase 3 small molecule active

    1 trial

  19. TACROLIMUS, ALPN-303 solution for injection in pre-filled syringe, TACROLIMUS, TACROLIMUS, ALPN-303 solution for injection, Test IMP without active substance, ALPN-303 Solution for Injection in Pre-filled Pen

    Vertex Pharmaceuticals (Australia) Pty.

    Primary Membranous Nephropathy

    phase 3 small molecule active

    1 trial

  20. TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Datopotamab deruxtecan

    AstraZeneca AB

    Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  21. TAGRISSO 80 mg film-coated tablets, CARBOPLATIN, CISPLATIN, PEMETREXED

    AstraZeneca AB

    Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.

    phase 3 small molecule active

    1 trial

  22. TAGRISSO 80 mg film-coated tablets, INFLIXIMAB, TAGRISSO 40 mg film-coated tablets, MYCOPHENOLATE MOFETIL, GLUCOSE, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Main cohort: Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer Osimertinib cohort: Open-label, Single arm for patients with unresected stage I/II, lymph done negative NSCLC harboring a sensitizing EGFR mutation

    phase 3 small molecule active

    1 trial

  23. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirmed, common sensitising EGFR mutations (Ex19del and L858R either alone or in combination with other EGFR mutations), following complete tumour resection with or without adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  24. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources